Accentia Biopharmaceuticals Inc.

Dr. O'Donnell has served as Chairman of the Board of Accentia Biopharmaceuticals, Inc. since November, 1998 and as CEO since May 2003. Dr O'Donnell is a 1975, summa cum laude graduate of the Johns Hopkins School of Medicine. He received his specialty training at the Wilmer Ophthalmological Institute, Johns Hopkins Hospital. He is the former Professor and Chairman, Dept of Ophthalmology, St Louis University School of Medicine. He is the Founder and Managing Partner of The Hopkins Capital Group (HCG), LLC, a leading biotech investment/business development company. The HCG specializes in early-stage investments in disruptive innovations in healthcare. Dr O'Donnell has published over 30 peer-reviewed scientific articles and he has been awarded 34 US Patents. He is the recipient of the 2000 Jules Stein Award from Retinitis Pigmentosa International.

Steven R. Arikian, M.D. began serving as a director in April 2002. Since November 2004, Dr. Arikian has served as President and Chief Operating Officer of Product Development and Market Services. In February 2005, his title was changed to President and Chief Operating Officer, Biopharmaceutical Products and Services. From January 2003 to November 2004, he was President of Pre-Market Services and Operations and from April 2002 to January 2003, he was President of Pre-Market Services. Since 1997, Dr. Arikian has served as the Chairman, Chief Executive Officer, and founder of our Analytica subsidiary, and September 2004, he has served and the Chairman and Chief Executive Officer of Biovest. Since 2003, Dr. Arikian has served as a director, and since 2004 has served as Chief Executive Officer, President, and Chairman, of Biovest International, Inc., our majority-owned, publicly held subsidiary. Dr. Arikian began providing pharmaceutical clients with Clinical and Outcomes Research services in 1988. He served as President of The Center for Health Outcomes and Economics at Bristol Myers Squibb from May 1995 to July 1997, where he supervised a staff of over 50 professionals responsible for development of global health outcomes research. He has designed and implemented research projects in the United States, Canada, Latin America and Europe. Dr. Arikian holds a faculty appointment at the Columbia University Mailman School of Public Health. He has also held faculty appointments at the University of Toronto and the University of Kentucky. He is widely published in the peer-reviewed literature and has been a frequent speaker at industry and trade group sponsored meetings on topics including Formulary Management, Pharmaceutical Pricing, Multi-National Health Economic Studies, and Pharmacoepidemiology. Dr. Arikian is a graduate of Fordham University with a degree in Biology and is also a graduate of the University of Catania (Italy) Medical School.

Samuel S. Duffey, Esq. has served as a director and our General Counsel since April 2003. Prior to that, Mr. Duffey practiced business law with Duffey and Dolan P.A. beginning in 1992. From February 2000, to September 2003, Mr. Duffey served as the non-executive chairman and as a member of the board of directors of Invisia, Inc., a small publicly held safety company, and from October 2001 to May 2004, Mr. Duffey also served as the non-executive chairman and as a member of the board of directors of FlashPoint International, Inc., a publicly held automotive parts company which is currently named Navitrak International Corporation. Mr. Duffey received his B.A. and J.D. degrees from Drake University.

Mr. Pearce recently retired as Senior Vice President, Financial Services of McKesson Corporation after 27 years with the firm. McKesson Corporation, a publicly traded Fortune 20 company (NYSE: MCK), is the leading provider of supply, information and care management products and services designed to reduce costs and improve quality across healthcare. Mr. Pearce held his last position since April 1999. Prior to this date he was treasurer of McKesson Corporation. Mr. Pearce currently serves on the board of directors and a member of the audit committee of BioDelivery Sciences International, Inc., a publicly traded drug delivery technology company (NASDAQ: BDSI). Mr. Pearce also currently serves on the advisory boards of Georgia Tech-Emory University BioEngineering Foundation and Hopkins Capital Group, a venture capital firm specializing in the healthcare field, and has previously served as a director and a member of the finance committee of XL Insurance. He is a graduate of Georgia Institute of Technology, where he earned a BS in Industrial Management and University of Texas, where he earned his MBA in finance.

David M. Schubert is President and Chief Business Officer of Accelerator Corporation. Prior to joining Accelerator in 2005, Mr. Schubert was the Founder and President of CellExSys, Inc, a biotechnology company focused on the creation of personalized medicines for the treatment of cancer and infectious diseases. In 1997, Mr. Schubert joined Targeted Genetics Corporation as Director, Communications and Strategic Relations and was promoted to Senior Director in 1999. He oversaw all investor relations and corporate communications activities and participated in a variety of business development initiatives. In April of 2000, he was appointed to the position of Senior Director, Strategic Initiatives, a position in which he focused on spinning out the company's assets in the cellular therapy area and the subsequent creation of CellExSys, Inc. in November of 2000. Previously, Mr. Schubert was a Biotechnology Research Associate at Vector Securities International (acquired by Prudential Securities). From 1994 to 1996 he was the Senior Market Manager for the Immunotherapy Division of Baxter Healthcare Corporation, where he developed and implemented strategic marketing programs for a multi-million dollar portfolio of products for utilization in the bone marrow transplantation and cellular therapies markets. From 1993 to 1994 he was the Assistant to the President of Baxter International's Biotech Europe Group located in Munich, Germany. Mr. Schubert holds an MBA degree with concentrations in Marketing and Management from The Pennsylvania State University, an MS in Biology with a concentration in Immunology from Utah State University and a BS in Biology and a BA in Psychology from Eastern Nazarene College in Quincy, Massachusetts. Mr. Schubert is a member of the Board of Directors of Accentia Biopharmaceuticals Inc (NASDAQ: ABPI).

Martin G. Baum began serving as one of our directors and as our President and Chief Operating Officer of Commercial Operations and Business Development in June 2003. In February 2005, his title was changed to President and Chief Operating Officer, Specialty Pharmaceuticals. He has also served as Chairman, President and Chief Executive Officer of our TEAMM subsidiary since its founding in July 2000. Prior to that, Mr. Baum served as Senior Vice President of Commercial Operations at DJ Pharmaceuticals, Inc., a specialty pharmaceutical company, since January 1999. Since June 2003, Mr. Baum has also been a director of Biovest International, Inc., our majority owned, publicly held subsidiary. Mr. Baum is a graduate of The University of Toledo, where he received B.S. degrees in Pre-Med and Business.

Steven J. Stogel has served as a director of our company since October 2005. Since 1990, Mr. Stogel has served as President of DFC Group, Inc., a St. Louis-based privately held real estate development and consulting company. From 1981 to 1990, Mr. Stogel served as a co-owner of McCormack, Baron & Associates, Inc., a real estate development and management company. Prior to that, Mr. Stogel was a partner in the St. Louis law firm of Rosenblum, Goldenhersh, Silverstein & Zafft, P.C., where he focused on real estate, tax, and securities law matters. Mr. Stogel holds a Bachelor s degree in Government from Clark University and a J.D. from Washington University.

Array